Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT00843726 | Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer | completed | Phase 2 | 98 | Roswell Park Cancer InstituteOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT02804776 | PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery(PROGRESS) | completed | Phase 2 | 15 | National Cancer Centre, SingaporeOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02785939 | Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 53 | SWOG Cancer Research NetworkNETWORK | 1 | May 27, 2021 | clinicaltrials |
| NCT02965378 | Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 43 | SWOG Cancer Research NetworkNETWORK | 2 | May 27, 2021 | clinicaltrials |
| NCT02646020 | Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment(EGFR-TKIs) | completed | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01076231 | Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery | completed | Phase 1 / Phase 2 | 34 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT00308750 | First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 218 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT03394118 | TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy | completed | Phase 2 | 63 | Asan Medical CenterOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT03595644 | Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 74 | Tongji HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01577654 | Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer(TARGET) | completed | Phase 2 | 203 | EndocyteINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT02450903 | LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01066234 | Adjuvant CCRT vs CT in Minimal N2 NSCLC | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02747953 | Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | completed | Phase 2 | 50 | Samsung Medical CenterOTHER | 0 | Mar 19, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02094573 | A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 2 | 222 | Ariad PharmaceuticalsINDUSTRY | 0 | Mar 15, 2021 | clinicaltrials |
| NCT03736837 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(ALTER-L004) | completed | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT00606502 | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | completed | Phase 2 | 201 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 5, 2021 | clinicaltrials |
| NCT01820754 | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)(TOP1201 IPI) | completed | Phase 2 | 24 | Duke UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03157089 | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung(LUX-Lung-IO) | completed | Phase 2 | 24 | Boehringer IngelheimINDUSTRY | 5 | Feb 23, 2021 | clinicaltrials |
| NCT00003860 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer | completed | Phase 2 | 36 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00219297 | Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT01945021 | Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | completed | Phase 2 | 129 | PfizerINDUSTRY | 4 | Feb 21, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | completed | Phase 2 | 20 | Emory UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01102231 | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 106 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02733250 | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer(URCOH-PMS-001) | completed | Phase 1 / Phase 2 | 10 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02577341 | Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | completed | Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT01635270 | Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma(midP) | completed | Phase 2 | 54 | Centre Leon BerardOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03044626 | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC(FORCE) | completed | Phase 2 | 101 | AIO-Studien-gGmbHOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01573702 | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | completed | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT02525653 | Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers | completed | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT01556191 | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR(LADIE) | completed | Phase 2 | 379 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT02574598 | MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | completed | Phase 2 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT01823068 | Vandetanib in Advanced NSCLC With RET Rearrangement | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2021source: clinicaltrials